Adial Pharmaceuticals (ADIL) Net Cash Flow (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Net Cash Flow of -$1.3 million for Q1 2026, down 251.57% sequentially from $855764.0 in Q3 2025, and up 6.33% YoY from -$1.2 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Net Cash Flow (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Net Cash Flow for 10 years, with the latest figure at -$1.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 6.33% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 517.42% YoY) and the FY2025 annual result came in at $2.1 million, up 130.73% from the prior year.
- Net Cash Flow retreated to -$1.3 million in Q1 2026 per ADIL's latest filing, from $855764.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $6.6 million in Q1 2022 and troughed at -$4.7 million in Q3 2022.
- A 5-year average of $274786.7 and a median of $83530.0 in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 417.43% in 2022, then jumped 2746.0% in 2024.
- Over 5 years, Net Cash Flow stood at $841248.0 in 2022, then jumped by 200.6% to $2.5 million in 2023, then declined by 5.99% to $2.4 million in 2024, then plunged by 64.0% to $855764.0 in 2025, then tumbled by 251.57% to -$1.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.3 million, $855764.0, and $3.5 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 18.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.30 Mn |
| Mar 31, 2026 | -1.30 Mn |
| Sep 30, 2025 | 855,764.00 |
| Sep 30, 2025 | 855,764.00 |
| Jun 30, 2025 | 3.55 Mn |
| Jun 30, 2025 | 3.55 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Jun 30, 2024 | -1.74 Mn |
| Jun 30, 2024 | -1.74 Mn |
| Mar 31, 2024 | 2.20 Mn |
| Mar 31, 2024 | 2.20 Mn |
| Dec 31, 2023 | 2.53 Mn |
| Dec 31, 2023 | 2.53 Mn |
| Sep 30, 2023 | 83,530.00 |
| Sep 30, 2023 | 83,530.00 |
| Jun 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | -1.89 Mn |